PF-00835231
Based on 4 publication(s) in Google Scholar
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.31%
- CAS No.: 870153-29-0
- 화학식: C24H32N4O6
- 분자량:472.53
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PF-00835231
More
Biological Activity
|
HIV-1 |
HRV3C 2.79 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H1-HeLa | CC50 |
>1260 μM
Compound: 4; PF-00835231
|
Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability measured after 2 to 5 days by XTT assay
Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability measured after 2 to 5 days by XTT assay
|
[PMID: 33054210] |
| H9 | CC50 |
>32 μM
Compound: 4; PF-00835231
|
Cytotoxicity against human H9 cells assessed as reduction in cell viability incubated for 7 days by XTT dye based analysis
Cytotoxicity against human H9 cells assessed as reduction in cell viability incubated for 7 days by XTT dye based analysis
|
[PMID: 33054210] |
| HEK-293T | CC50 |
>50000 nM
Compound: PF-00835231
|
Cytotoxicity against HEK293T cells transfected with ACE2 and TMPRSS2 assessed as reduction in cell viability
Cytotoxicity against HEK293T cells transfected with ACE2 and TMPRSS2 assessed as reduction in cell viability
|
[PMID: 36229406] |
| Huh-7 | CC50 |
>320 μM
Compound: 4; PF-00835231
|
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability
|
[PMID: 33054210] |
| MRC5 | CC50 |
>100 μM
Compound: 4; PF-00835231
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 1 to 5 days by XTT dye based assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 1 to 5 days by XTT dye based assay
|
[PMID: 33054210] |
| MRC5 | CC50 |
>40 μM
Compound: 4; PF-00835231
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 4 days by XTT dye based assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 4 days by XTT dye based assay
|
[PMID: 33054210] |
| Vero 76 | CC50 |
452 μM
Compound: 4; PF-00835231
|
Cytotoxicity against African green monkey Vero 76 cells measured after 66 hrs by neutral red method or cell titer glo-based luminescence assay
Cytotoxicity against African green monkey Vero 76 cells measured after 66 hrs by neutral red method or cell titer glo-based luminescence assay
|
[PMID: 33054210] |
| Vero C1008 | CC50 |
>50000 nM
Compound: PF-00835231
|
Cytotoxicity against African green monkey Vero E6 cells transfected with TMPRSS2 assessed as reduction in cell viability
Cytotoxicity against African green monkey Vero E6 cells transfected with TMPRSS2 assessed as reduction in cell viability
|
[PMID: 36229406] |
| Vero C1008 | EC50 |
0.23 μM
Compound: PF-00835231
|
Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 3 days
Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 3 days
|
[PMID: 36475694] |
| Vero C1008 | EC50 |
21.7 nM
Compound: PF-00835231
|
Antiviral activity against SARS-CoV-2 variant Omicron BA.2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against SARS-CoV-2 variant Omicron BA.2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect
|
[PMID: 37229831] |
PF-00835231 effectively inhibits SARS-CoV-2 USA-WA1/2020, with an EC50 of 0.221 μM after 24 hours and 0.158 μM after 48 hours[2].
PF-00835231 also inhibits USA/NYU-VC-003/2020, with an EC50 of 0.184 μM after 24 hours[2].
The IC50 value of PF-00835231 against HIV-1 and HCV protease is greater than 10 μM, but it can inhibit the rhinovirus HRV3C protease with an IC50 of about 2.79 μM, showing strong inhibitory effects and broad-spectrum activity against coronavirus Mp[3].
PF-00835231 exhibits inhibitory effects against infections of the SARS-CoV-2 Wuhan strain, Washington strain 1, and Belgium/GHB-03021/2020 strain in A549, Calu-1, Vero E6, Vero E6-enACE2 (ACE2-rich Vero E6 kidney cells), and Vero E6-EGFP (Vero E6 cells continuously expressing EGFP), with EC50 values ranging from 24.7 nM to 88900 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 870153-29-0
-
Appearance Solid
-
분자량 472.53
-
화학식 C24H32N4O6
-
Color White to off-white
-
SMILES
O=C(C(N1)=CC2=C1C=CC=C2OC)N[C@H](C(N[C@@H](C[C@H]3C(NCC3)=O)C(CO)=O)=O)CC(C)C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Virol Sin
2025 Mar 19:S1995-820X(25)00028-8. PMID: 40118151 -
J Virol
Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors. [Abstract]2022 Sep 14;96(17):e0090722. PMID: 36000844 -
Adv Biol (Weinh)
Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System. [Abstract]2024 Nov;8(11):e2300511. PMID: 39123296 -
용액&용해도
DMSO : 250 mg/mL (529.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
-
Handling Instructions (2659 KB)
References
[1]. Robert L Hoffman, et al. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J Med Chem. 2020 Nov 12;63(21):12725-12747. [Content Brief]
[2]. de Vries M, et al. A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880. [Content Brief]
[3]. Wujun Chen, wt al. Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front Pharmacol. 2022 Nov 11:13:1035969. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1163 mL | 10.5813 mL | 21.1627 mL | 52.9067 mL |
| 5 mM | 0.4233 mL | 2.1163 mL | 4.2325 mL | 10.5813 mL | |
| 10 mM | 0.2116 mL | 1.0581 mL | 2.1163 mL | 5.2907 mL | |
| 15 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.5271 mL | |
| 20 mM | 0.1058 mL | 0.5291 mL | 1.0581 mL | 2.6453 mL | |
| 25 mM | 0.0847 mL | 0.4233 mL | 0.8465 mL | 2.1163 mL | |
| 30 mM | 0.0705 mL | 0.3527 mL | 0.7054 mL | 1.7636 mL | |
| 40 mM | 0.0529 mL | 0.2645 mL | 0.5291 mL | 1.3227 mL | |
| 50 mM | 0.0423 mL | 0.2116 mL | 0.4233 mL | 1.0581 mL | |
| 60 mM | 0.0353 mL | 0.1764 mL | 0.3527 mL | 0.8818 mL | |
| 80 mM | 0.0265 mL | 0.1323 mL | 0.2645 mL | 0.6613 mL | |
| 100 mM | 0.0212 mL | 0.1058 mL | 0.2116 mL | 0.5291 mL |
PF-00835231 Related Classifications
HY-137048 Related Classifications
Powered by Bioz